Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H5N1 - GSK

X
Drug Profile

Influenza A virus vaccine H5N1 - GSK

Alternative Names: (Pre)-pandemic vaccine against H5N1 inactivated split - monovalent (Dresden) - GSK; (Pre)-pandemic vaccine against H5N1 inactivated split - monovalent (Quebec) - GSK; Adjupanrix; GSK 2590066A; GSK 2592984A; GSK1119711A; GSK1557484A; GSK1562902A; H5N1 (pre-)pandemic influenza virus vaccine - GSK; H5N1 Clade 1 strain (pre-)pandemic influenza vaccine - GSK; Pandemic vaccine against H5N1 inactivated split - monovalent (Quebec) - GSK; Pre-pandemic influenza vaccine - GSK; Prepandrix; Pumarix; Q-Pan H5N1; Split virion, inactivated, adjuvanted (pre-)pandemic H5N1 influenza vaccine - GSK

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; Japan Vaccine
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 30 Jul 2019 Influenza A virus vaccine H5N1 is not yet available for Influenza A virus H5N1 subtype (Prevention) in Canada, Iceland, Liechtenstein, Norway, Switzerland, USA (IM)
  • 13 Feb 2018 GlaxoSmithKline completes a phase II trial in Influenza-A virus H5N1 subtype (Prevention, In infants, In children) in Taiwan, Thailand (IM) (NCT02719743)
  • 01 Jul 2016 Phase-II clinical trials in Influenza-A virus H5N1 subtype (Prevention, In infants, In children) in Taiwan, Thailand (IM) (NCT02719743)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top